Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a user dealing with androgenetic alopecia using minoxidil 5% and attempting to import Adenogen tonic from Japan, which was rejected by Spanish customs. The user seeks advice on obtaining Adenogen or Adenovital within the EU or tips for passing customs.

A user with hair loss is considering starting a business selling hair loss treatments, including RU58841, low-dose topical finasteride with optional minoxidil and tretinoin, and topical melatonin. They are also contemplating offering Pyrilutamide and other unique topicals, seeking feedback on interest and suggestions for their potential store.

A 20-year-old is considering switching from finasteride to dutasteride during a steroid cycle to better manage hair loss, then returning to finasteride afterward. They are concerned about the risks of post-finasteride syndrome from frequently changing medications.

A user is considering starting spironolactone for hair loss without consulting a dermatologist, as previous dermatologists only recommended biotin, vitamins, or PRP. The user notes that spironolactone is affordable in their country.

A 32-year-old male used 1.25mg oral finasteride daily and 1ml topical minoxidil twice daily for 24 weeks, experiencing improved skin and hair growth with initial side effects that resolved after three weeks. He plans to try dermastamping to address a stubborn cowlick area.

The conversation provides a guide on using finasteride for hair loss, suggesting to start with a quarter of a 1mg pill daily after ensuring estradiol levels are within a specific range, and potentially increasing the dose if no side effects occur. It also recommends supplements like DIM, Calcium d-glucarate, and Zinc to manage high estradiol levels and side effects from finasteride.

The conversation discusses using RU58841 at a 2% concentration as an alternative due to side effects from finasteride. The user plans to start with a lower concentration and increase if necessary.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

A 32-year-old male started taking 0.5mg of finasteride daily for hair thinning and, after 8 weeks, experienced a 70% reduction in DHT and an increase in estradiol; he is currently in the shedding phase of treatment and questioning if the dosage is correct based on his DHT levels. He began with a lower dose due to already low normal testosterone and DHT levels.

A 35-year-old man has been using a topical solution with finasteride, minoxidil, retinoic acid, and hydrocortisone for hair regrowth, experiencing minor side effects. He plans to remove hydrocortisone due to potential long-term health risks.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

OP is considering mixing finasteride pills with a 60ml bottle of Redensyl to create a topical treatment. The discussion focuses on the feasibility and effectiveness of this approach for hair loss.

Users discuss making topical finasteride solutions by dissolving crushed tablets in ethanol and propylene glycol, with concerns about residue affecting effectiveness. They also mention using minoxidil and oral finasteride, noting some hair regrowth and no side effects from topical use.

A user is concerned about using more minoxidil than prescribed to cover their hair loss area and mentions taking spironolactone pills. Another user advises against men taking oral spironolactone due to significant hormonal effects.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.

An 18-year-old is using a high-dose treatment for hair loss, including 2.5 mg dutasteride, topical minoxidil, and injectable GHK-Cu, despite minimal hair loss. Many users suggest reducing the dutasteride dose due to potential side effects and recommend starting with finasteride instead.

The user experienced significant hair regrowth using a treatment regimen including finasteride, oral and topical minoxidil, RU58841, red light therapy, microneedling, and various supplements. They switched from dutasteride to finasteride due to side effects and reported improved results and well-being.

The user stopped using finasteride due to side effects and switched to RU58841, which seems to be working for hair regrowth. They are considering RU58841 and minoxidil as long-term treatments, while others discuss the safety and effectiveness of these options.

Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conversation discusses hair loss treatments, specifically progesterone therapy with hydrocortisone butyrate, and the use of dutasteride and finasteride. Opinions vary on the effectiveness and side effects of these treatments, with some users advocating for acceptance of balding if treatments are not suitable.

After gyno surgery, OP is considering restarting finasteride at a lower dose (0.25mg/0.5mg) or switching to topical to reduce the risk of gyno recurrence. Lower doses and topical application may lessen side effects due to reduced systemic absorption.

A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.

A user is using a Finoxidil topical spray and is curious if oral Finasteride would be more effective, considering they are already on a DHT blocker called Cyproterone. They are concerned about the potential impact of oral Finasteride on their transition.

The user experienced significant hair regrowth using 5mg oral Minoxidil and 0.5mg oral Dutasteride daily, with no side effects except increased body and eyebrow hair. They are concerned about progress plateauing but have not experienced shedding.